Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
Cash from Financing Activities
Intra-Cellular Therapies Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Cash from Financing Activities
$17.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
92%
|
CAGR 10-Years
-8%
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Intra-Cellular Therapies Inc's Cash from Financing Activities?
Cash from Financing Activities
17.8m
USD
Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Cash from Financing Activities amounts to 17.8m USD.
What is Intra-Cellular Therapies Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-8%
Over the last year, the Cash from Financing Activities growth was -96%. The average annual Cash from Financing Activities growth rates for Intra-Cellular Therapies Inc have been -70% over the past three years , 92% over the past five years , and -8% over the past ten years .